Trials / Terminated
TerminatedNCT01167088
A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD)
A Double-blind Randomised Placebo-controlled Multicentre Study of 40mg MitoQ and Placebo for the Treatment of Participants With Raised Liver Enzymes Due to Non-Alcoholic Fatty Liver Disease (NAFLD)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Antipodean Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate whether a new medicine, called mitoquinone, will reduce raised liver enzymes due to NAFLD and to see if it is safe.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mitoquinone mesylate | 2 tablets to be taken daily upon wakening, with a glass of water and at least one hour before food. |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-06-01
- Completion
- 2011-07-01
- First posted
- 2010-07-22
- Last updated
- 2011-06-01
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01167088. Inclusion in this directory is not an endorsement.